Literature DB >> 15257943

TP53 codon 72 polymorphism in patients with chronic myeloid leukemia.

Gaetano Bergamaschi, Serena Merante, Ester Orlandi, Anna Galli, Paolo Bernasconi, Mario Cazzola.   

Abstract

A single nucleotide polymorphism at TP53 codon 72 means that two alleles exist: A1 (proline residue, Pro72) and A2 (arginine residue, Arg72). The Pro72 variant of p53 has a lower apoptotic potential. We found that allele A1 was more frequent in patients with chronic myeloid leukemia (CML) than in controls, and among CML patients who had no cytogenetic response than among responders.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15257943

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  18 in total

1.  p53 Pro72Arg polymorphism and prostate cancer in men of African descent.

Authors:  L Ricks-Santi; T Mason; V Apprey; C Ahaghotu; A McLauchlin; D Josey; G Bonney; G M Dunston
Journal:  Prostate       Date:  2010-12-01       Impact factor: 4.104

2.  Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.

Authors:  Hans-Guido Wendel; Elisa de Stanchina; Enriqué Cepero; Sagarika Ray; Michael Emig; Jordan S Fridman; Darren R Veach; William G Bornmann; Bayard Clarkson; W Richard McCombie; Scott C Kogan; Andreas Hochhaus; Scott W Lowe
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

3.  MTHFR A1298C and C677T gene polymorphisms and susceptibility to chronic myeloid leukemia in Egypt.

Authors:  Rabab M Aly; Mona M Taalab; Hayam F Ghazy
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

4.  Lung cancer risk in relation to TP53 codon 47 and codon 72 polymorphism in Bangladeshi population.

Authors:  Md Shaki Mostaid; Maizbha Uddin Ahmed; Mohammad Safiqul Islam; Muhammad Shahdaat Bin Sayeed; Abul Hasnat
Journal:  Tumour Biol       Date:  2014-07-18

5.  p53 codon 72 polymorphism and hematological cancer risk: an update meta-analysis.

Authors:  Yu Weng; Liqin Lu; Guorong Yuan; Jing Guo; Zhizhong Zhang; Xinyou Xie; Guangdi Chen; Jun Zhang
Journal:  PLoS One       Date:  2012-09-24       Impact factor: 3.240

6.  TP53 codon 72 Gene Polymorphism Paradox in Associated with Various Carcinoma Incidences, Invasiveness and Chemotherapy Responses.

Authors:  Hung-Yu Lin; Chun-Hsiung Huang; Wen-Jen Wu; Li-Ching Chang; For-Wey Lung
Journal:  Int J Biomed Sci       Date:  2008-12

7.  In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis.

Authors:  Isrid Sturm; Andrew G Bosanquet; Michael Hummel; Bernd Dörken; Peter T Daniel
Journal:  BMC Cancer       Date:  2005-08-18       Impact factor: 4.430

Review 8.  Genetic modifiers of cancer risk in Lynch syndrome: a review.

Authors:  Bente A Talseth-Palmer; Juul T Wijnen; Desma M Grice; Rodney J Scott
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

9.  Response to microtubule-interacting agents in primary epithelial ovarian cancer cells.

Authors:  Ilenia Pellicciotta; Chia-Ping Huang Yang; Charis A Venditti; Gary L Goldberg; Shohreh Shahabi
Journal:  Cancer Cell Int       Date:  2013-04-10       Impact factor: 5.722

10.  The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes.

Authors:  K L McGraw; L M Zhang; D E Rollison; A A Basiorka; W Fulp; B Rawal; A Jerez; D L Billingsley; H-Y Lin; S E Kurtin; S Yoder; Y Zhang; K Guinta; M Mallo; F Solé; M J Calasanz; J Cervera; E Such; T González; T J Nevill; T Haferlach; A E Smith; A Kulasekararaj; G Mufti; A Karsan; J P Maciejewski; L Sokol; P K Epling-Burnette; S Wei; A F List
Journal:  Blood Cancer J       Date:  2015-03-13       Impact factor: 11.037
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.